Trials / Completed
CompletedNCT03743376
The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients
The HIV Functional Cure Potential of UB-421: A Phase II, Randomized, Open-label, Controlled, 48 Week, Proof of Concept Study, to Evaluate the Safety of UB-421 in Combination With Standard Antiretroviral Therapy (ART) and the Efficacy of HIV Reservoir Reduction as Compared With ART Alone in ART Stabilized HIV-1 Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- United BioPharma · Industry
- Sex
- All
- Age
- 20 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluate the safety of UB-421 in combination with standard antiretroviral therapy (ART) and the efficacy of HIV reservoir reduction as compared with ART alone in ART stabilized HIV-1 patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | UB-421(25 mg/kg) Q2W | Monoclonal antibody by IV infusion plus standard ART |
| BIOLOGICAL | UB-421(25 mg/kg) Q4W | Monoclonal antibody by IV infusion plus standard ART |
Timeline
- Start date
- 2018-12-12
- Primary completion
- 2020-10-15
- Completion
- 2021-12-31
- First posted
- 2018-11-16
- Last updated
- 2022-05-13
Locations
3 sites across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT03743376. Inclusion in this directory is not an endorsement.